These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3365919)

  • 1. Inhibition of desipramine 2-hydroxylation by quinidine and quinine.
    Steiner E; Dumont E; Spina E; Dahlqvist R
    Clin Pharmacol Ther; 1988 May; 43(5):577-81. PubMed ID: 3365919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
    Spina E; Steiner E; Dumont E; Dahlqvist R
    Psychopharmacol Ser; 1989; 7():201-5. PubMed ID: 2687858
    [No Abstract]   [Full Text] [Related]  

  • 3. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
    Steiner E; Spina E
    Clin Pharmacol Ther; 1987 Sep; 42(3):278-82. PubMed ID: 3621781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine.
    Spina E; Arena A; Pisani F
    Ther Drug Monit; 1987 Jun; 9(2):129-33. PubMed ID: 3617150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E; Steiner E; Ericsson O; Sjöqvist F
    Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active metabolites of imipramine and desipramine in man.
    Potter WZ; Calil HM; Sutfin TA; Zavadil AP; Jusko WJ; Rapoport J; Goodwin FK
    Clin Pharmacol Ther; 1982 Mar; 31(3):393-401. PubMed ID: 7060321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
    J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Cotreau-Bibbo MM; Duan SX; Harmatz JS; Shader RI
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1278-83. PubMed ID: 8138941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
    Ayesh R; Dawling S; Hayler A; Oates NS; Cholerton S; Widdop B; Idle JR; Smith RL
    Chirality; 1991; 3(1):14-8. PubMed ID: 2039678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.
    von Bahr C; Spina E; Birgersson C; Ericsson O; Göransson M; Henthorn T; Sjöqvist F
    Biochem Pharmacol; 1985 Jul; 34(14):2501-5. PubMed ID: 4015690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenobarbital induces the 2-hydroxylation of desipramine.
    Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
    Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desipramine hydroxylation: variability and effect of antipsychotic drugs.
    Bock JL; Nelson JC; Gray S; Jatlow PI
    Clin Pharmacol Ther; 1983 Mar; 33(3):322-8. PubMed ID: 6130865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.
    Cooke RG; Warsh JJ; Stancer HC; Reed KL; Persad E
    Clin Pharmacol Ther; 1984 Sep; 36(3):343-9. PubMed ID: 6467794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine.
    Hedman A; Angelin B; Arvidsson A; Dahlqvist R; Nilsson B
    Clin Pharmacol Ther; 1990 Jan; 47(1):20-6. PubMed ID: 2295215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
    Muralidharan G; Hawes EM; McKay G; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1991; 41(5):471-4. PubMed ID: 1761076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of carbamazepine on the 2-hydroxylation of desipramine.
    Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
    Psychopharmacology (Berl); 1995 Feb; 117(4):413-6. PubMed ID: 7604141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
    Sjöqvist F; Bertilsson L
    Prog Clin Biol Res; 1986; 214():169-88. PubMed ID: 3523507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.